SI-BONE(US:SIBN) Globenewswire·2026-01-12 14:00Core Insights - SI-BONE, Inc. anticipates worldwide revenue for Fiscal Year 2025 to be between $200.8 million and $200.9 million, indicating a growth of approximately 20% [1][6] - The company reported fourth quarter revenue between $56.2 million and $56.3 million, reflecting a growth of around 15% compared to the prior year [6] - U.S. revenue for the fourth quarter is projected to be between $53.3 million and $53.4 million, showing a growth of about 14% [6] Fiscal Year 2025 Summary - The preliminary revenue for Fiscal Year 2025 is expected to be between $200.8 million and $200.9 million, with a growth rate of approximately 20% [1][6] - U.S. revenue for the fiscal year is projected to be between $190.9 million and $191.0 million, representing a growth of around 21% [6] Fourth Quarter 2025 Summary - The fourth quarter revenue is estimated to be between $56.2 million and $56.3 million, which is a growth of approximately 15% year-over-year [6] - The U.S. revenue for the fourth quarter is expected to be between $53.3 million and $53.4 million, indicating a growth of about 14% [6] - The company has approximately 1,640 active physicians in the U.S., an increase of 250 physicians, representing an 18% growth [6] - Cash and cash equivalents are estimated to be around $147.7 million, implying a net cash generation of approximately $2.0 million in the quarter [6] Company Overview - SI-BONE, Inc. is recognized as a global leader in developing procedural solutions for clinical challenges related to compromised bone [3] - The company has a strong expertise in additive manufacturing, leading to market-leading applications in areas such as SI joint fusion, adult spinal deformity, and pelvic trauma [3] - Since its inception in 2009, SI-BONE has supported over 140,000 procedures, backed by a substantial body of clinical evidence including four randomized controlled trials and over 200 peer-reviewed publications [3]